· Regulation · Regulation Desk
The first publicly reported peptide-specific sterile compounding recall of 2026 lands while FDA's decision on the PCAC peptide recommendations is still pending, reinforcing the agency's standards-gap argument.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.